Table 2.
Included (n=16) | Excluded (n=16) | |
---|---|---|
Age, years, median (IQR) | 61.5 (9.5) | 65.5 (11.5) |
Sex, females, n (%) | 5 (31) | 11 (68) |
Duration of disease, years, median (IQR) | 13.0 (8.0) | 13.5 (4.3) |
Duration of medication, years, median (IQR) | 11.5 (7.0) | 11.0 (4.5) |
Hoehn and Yahr stage, median (IQR) | 3.0 (1.0) | 3.0 (0.3) |
Final stimulation setting, median (IQR) | ||
Pulse, microseconds | 60.0 (0.00) | 60.0 (7.5) |
Hz | 130.0 (0.0) | 130.0 (15.0) |
Volts | 1.68 (1.21) | 2.00 (0.95) |
First LEDD | 1216 (614) | 1281 (473) |
Final LEDD | 555 (315) | 713 (334) |
Dominant affected side, right (%) | 12 (75) | 9 (56) |
IQR, interquartile range; LEDD, levodopa equivalent daily dose.